Crews’ laboratory developed a tau PhosTAC that can achieve a similar effect as Zheng’s tau DEPTAC, indicating that tau PhosTAC is also a promising approach for treating tauopathies, including AD [61]. This evidence concerns the gene MAPT and Alzheimer disease.